Clinical trials: Myopic Children
Myopia
CHAMP: Study of NVK-002 in Children With Myopia
Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period.
- Trial name
- NCT03350620
- Testing
- NVK-002 Concentration 1, NVK-002 Concentration 2
- Where
- 26 sites in United States, Hungary and 4 more
- Volunteers
- 670 people
- Sponsor
- Vyluma, Inc.
Nearsightedness, Near Sightedness
The Safety and Efficacy of SYD-101 in Children With Myopia
Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA.
- Conditions
- Nearsightedness, Near Sightedness, Near-sightedness
- Trial name
- STAR (NCT03918915)
- Testing
- SYD-101 0.01%, SYD-101 0.03%, Vehicle
- Where
- 47 sites in United States, Austria and 1 more
- Volunteers
- 852 people
- Sponsor
- Sydnexis, Inc.